AzTrials
AzTrials

Myocardial InjuryNCT06287372

Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia

An observational study of Myocardial Injury and Cardiac Surgery, run by Damascus University at 1 site in Syria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the present study was to investigate intra-operative changes in markers of myocardial injury and myocardial intracellular amino acids during ischemia and reperfusion, comparing two methods of myocardial protection; Calafiore intermittent antegrade warm blood cardioplegia or modified del Nido intermittent… Read more about this study

Who is it for?
Any age
What is being tested?
Cardioplegic solution
How many people
20 participants
Where
1 siteSyria
Study dates
4 Jul 2022to 4 Jul 2023
How long will I take part?
7 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study

Who may be able to join

  • All consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study.

Who cannot join

  • Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery.

Trial locations and contacts

1 site in 1 country.

Syria1 site
  • Damascus University Cardiac Surgery Hospital

    Damascus

Other trials in Syria

About this study

Official title: Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegic Solutions in Routine Coronary Artery Bypass Surgery

The aim of the present study was to investigate intra-operative changes in markers of myocardial injury and myocardial intracellular amino acids during ischemia and reperfusion, comparing two methods of myocardial protection; Calafiore intermittent antegrade warm blood cardioplegia or modified del Nido intermittent antegrade cold blood cardioplegia in routine coronary artery bypass grafting procedures.

Read the detailed description

Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study. Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery. Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:

  • Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously.
  • Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).

Each patient enrolled in the study gave a written informed consent for the publication of the study data, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the local human research committee number 171 dated 13 April 2022

Collection of blood samples and myocardial biopsies Peripheral blood samples were collected immediately prior to surgery and at 4, 12, 24 and 48 hours postoperatively and were used for determination of blood concentrations of cardiac enzymes (CK-MB and troponin I).

Myocardial biopsies (4-14 mg wet weight) were taken using a Tru-cut needle from the apex of the left ventricle in every patient as follows:

  • Biopsy 1: "Resting specimen", immediately after beginning of extracorporeal circulation.
  • Biopsy 2: "Ischemic specimen", 30 minutes after application of the aortic cross-clamp.
  • Biopsy 3: "Reperfusion specimen", 20 minutes following the removal of aortic cross-clamp.

Each specimen was immediately snap-frozen in liquid nitrogen (-185 degrees C) until processing for the analyses of amino acids and lactic acid.

Determination of cardiac enzymes (CK-MB and troponin I) Analyses were carried out using an immunofluorescence scanner (iChroma II, Boditech Med Incorporated, Korea and Obelis s.a, Belgium). Blood levels of CK-MB were expressed as mg/dl and levels of troponin I were expressed as ng/ml.

Determination of myocardial amino acid and lactic acid concentrations Each frozen biopsy specimen was weighed (Laboratory Analytical Balance, Sartorius, Germany), crushed in liquid nitrogen and homogenized in 1000 micro mol of 0.9% normal saline. A 400 micro mol sample of the homogenate was transferred to an Eppendorf tube and 100 micro mol of HPLC water was added. Each sample was then stored at 4 degrees C for one hour, after which it was centrifuged at 10000 round/min for 5 minutes. A 400 micro mol sample of the supernatant was filtered through a Vivaspin® 500 membrane filter 0.2 µm (Satorius, Germany), transferred to an Eppendorf tube and was centrifuged at 10000 round/min for 5 minutes. A 300 micro mol sample of the filtrate was transferred to an Eppendorf tube and an equal volume of sample dilution buffer (membraPure, Germany) was added. This solution was used for determining the concentrations of 7 amino acids (alanine, glutamine, glutamic acid, glycine, lysine, ornithine and taurine) using the A300 Amino Acid Analyzer (ARACUS, membraPure, Germany). Lactic acid concentrations were also measured using a dedicated plasma lactate determination kit and analyzer (LACT2, cobas, Roche Diagnostics GmbH, Germany). Concentrations of amino acids and lactic acid were expressed as micro mol/g wet weight.

Being tested
Cardioplegic solution
Keywords
cardioplegia, coronary artery bypass grafting, amino acid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cardioplegic solutionOther

    Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection

Study groups in NCT06287372
Study groupRoleWhat they receive
Group 1: Calafiore cardioplegiaPatients were randomly assigned to undergo surgery using one of two methods for myocardial protection: • Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously.
Receives: Other: Cardioplegic solution
Group 2: del Nido cardioplegia• Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).
Receives: Other: Cardioplegic solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in markers of myocardial injury

    Changes in release of myocardial CK-MB and troponin I

    Measured: 4, 12, 24 and 48 hours postoperatively

Secondary outcomes (1)
  1. Changes in myocardial amino acid concentrations

    Changes in myocardial intracellular concentrations of 7 amino acids (alanine, glutamine, glutamic acid, glycine, lysine, ornithine and taurine)

    Measured: 2-3 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Mar 2024
  2. Study start4 Jul 2022
  3. Primary completion4 Jul 2023
  4. Study completion4 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
20 participants (actual)
Target duration
7 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT06287372
Sponsor's protocol ID
3261
Status last verified
Mar 2026
First submitted
23 Feb 2024
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Data will be uploaded on (figshare) data repository site

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Injury and Cardiac Surgery, run by Damascus University at 1 site in Syria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in markers of myocardial injury (time frame: 4, 12, 24 and 48 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in